{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:57:58Z","timestamp":1791917878535,"version":"4.3.4"},"reference-count":20,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,1,23]],"date-time":"2015-01-23T00:00:00Z","timestamp":1421971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Metabolism Res"],"published-print":{"date-parts":[[2015,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>To ascertain which demographic, clinical, and microbiological factors might affect clinical outcomes of patients with diabetic foot infections, excluding known osteomyelitis, by analysing Clinical Assessment Program and Teflaro\u00ae Utilization Registry study data of patients treated with ceftaroline fosamil.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>At participating study centres, we collected data by randomized selection and chart review, including patient demographics, co\u2010morbidities, infecting pathogens, antibiotic use, surgical interventions, and clinical response. Evaluable patients were those with data sufficient to determine clinical outcome. Clinical success was defined as clinical cure with no use of other antibiotics or clinical improvement with a switch to oral antibiotic therapy at the end of intravenous ceftaroline fosamil treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 201 patients (mean age 61.7\u00a0years, mean body mass index 33.2 and 57% male patients), 40% had peripheral vascular disease. Prior antibiotic therapy had been given to 161 (80%) of the patients, most commonly with vancomycin and\/or piperacillin\u2013tazobactam. Patients received ceftaroline fosamil for mean duration of 6.1\u00a0days (range 1\u201330), as monotherapy in 130 (65%) patients and concurrently with other antibiotics in 71 (35%). Bacterial pathogens were identified in 114 (57%) of the patients; methicillin\u2010resistant <jats:italic>Staphylococcus aureus<\/jats:italic> and methicillin\u2010sensitive <jats:italic>S<\/jats:italic>. <jats:italic>aureus<\/jats:italic> were isolated from 56 (49%) and 28 (25%) of culture\u2010positive patients respectively. Clinical success was noted in 81% of patients and was not significantly associated with co\u2010morbidities, pathogen type, or need for surgical intervention.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Ceftaroline fosamil treatment of diabetic foot infections was associated with high clinical success, including inpatients with obesity, co\u2010morbidities, or methicillin\u2010resistant <jats:italic>Staphylococcus aureus<\/jats:italic> or mixed infections or requiring surgical intervention. Copyright \u00a9 2014 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/dmrr.2624","type":"journal-article","created":{"date-parts":[[2014,11,22]],"date-time":"2014-11-22T00:14:22Z","timestamp":1416615262000},"page":"395-401","source":"Crossref","is-referenced-by-count":25,"title":["Ceftaroline fosamil for treatment of diabetic foot infections: the CAPTURE study experience"],"prefix":"10.1002","volume":"31","author":[{"given":"Benjamin A.","family":"Lipsky","sequence":"first","affiliation":[{"name":"University of Oxford  Oxford UK"},{"name":"University of Geneva  Geneva Switzerland"},{"name":"University of Washington  Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad M.","family":"Cannon","sequence":"additional","affiliation":[{"name":"University of Kansas Hospital Department of Emergency Medicine  Kansas City KS USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananthakrishnan","family":"Ramani","sequence":"additional","affiliation":[{"name":"Mountainview Medical Practice Columbia Memorial Hospital  Hudson NS USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Jandourek","sequence":"additional","affiliation":[{"name":"Cerexa, Inc.  Oakland CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anibal","family":"Calmaggi","sequence":"additional","affiliation":[{"name":"Cerexa, Inc.  Oakland CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. D.","family":"Friedland","sequence":"additional","affiliation":[{"name":"Cerexa, Inc.  Oakland CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie J. C.","family":"Goldstein","sequence":"additional","affiliation":[{"name":"UCLA School of Medicine  Los Angeles CA USA"},{"name":"R M Alden Research Laboratory  Santa Monica CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,1,23]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis346"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1586\/eri.10.122"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61779-791-0_18"},{"key":"e_1_2_8_5_1","first-page":"81","article-title":"Bacteriology of diabetic foot ulcers","volume":"34","author":"Ramani A","year":"1991","journal-title":"Indian J Pathol Microbiol"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.03.019"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/11538070-000000000-00000"},{"issue":"3","key":"e_1_2_8_8_1","first-page":"3","article-title":"The treatment of diabetic foot infections","volume":"65","author":"Powlson AS","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2011.05.003"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v2.i2.24"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1086\/380449"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh531"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67694-5"},{"key":"e_1_2_8_14_1","first-page":"3612","article-title":"Antimicrobial activity and spectrum of PPI\u20100903\u00a0M (T\u201091825) a novel cephalosporin, tested against a worldwide collection of clinical strains","volume":"51","author":"Sader HS","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp503"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00019-10"},{"issue":"4","key":"e_1_2_8_17_1","first-page":"41","article-title":"CANVAS 1: the first Phase III, randomised, double\u2010blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin\u2010structure infections","volume":"65","author":"Corey GR","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"e_1_2_8_18_1","first-page":"53","article-title":"CANVAS 2: the second Phase III, randomised, double\u2010blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin\u2010structure infections","volume":"65","author":"Wilcox MH","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"e_1_2_8_19_1","unstructured":"U. S. Food and Drug Administration.Guidance for industry: Uncomplicated and complicated skin and skin structure infections \u2010 developing antimicrobial drugs for treatment.1998. U. S. Food and Drug Administration Rockville MD."},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1086\/655827"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1179\/1973947813Y.0000000144"}],"container-title":["Diabetes\/Metabolism Research and Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fdmrr.2624","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dmrr.2624","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T14:16:47Z","timestamp":1696601807000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/dmrr.2624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,23]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["10.1002\/dmrr.2624"],"URL":"https:\/\/doi.org\/10.1002\/dmrr.2624","archive":["Portico"],"relation":{},"ISSN":["1520-7552","1520-7560"],"issn-type":[{"value":"1520-7552","type":"print"},{"value":"1520-7560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,23]]}}}